Search clinical trials for: retaspimycin hydrochloride (IPI-504)

Total 282 results

Infinity Pharmaceuticals, Inc.
AstraZeneca; MedImmune LLC

Terminated

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Gastrointestinal Stromal Tumors
Infinity Pharmaceuticals, Inc.

Completed

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Infinity Pharmaceuticals, Inc.

Terminated

IPI-504 in NSCLC Patients With ALK Translocations

Lung Cancer | Stage IV Lung Cancer | Stage IIIb Lung Cancer

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Gastrointestinal Stromal Tumors | Soft Tissue Sarcomas

United States, Canada
Infinity Pharmaceuticals, Inc.

Withdrawn

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

Multiple Myeloma

United States
Infinity Pharmaceuticals, Inc.

Terminated

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
MedImmune LLC

Withdrawn

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Breast Cancer

United States
Infinity Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer (IPI-504-04)

Prostatic Neoplasms | Prostate Cancer | Cancer of the Prostate

United States
Infinity Pharmaceuticals, Inc.

Completed

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Hungary, Taiwan, Korea, Republic of, Russian Federation, Romania
Bausch Health Americas, Inc.

Completed

Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

Onychomycosis

United States, Dominican Republic
Infinity Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Breast Cancer | Metastatic Breast Cancer | HER2 Positive Breast Cancer | Cancer of the Breast

United States, Spain
ESSA Pharmaceuticals

Terminated

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Genital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, Male

United States, Canada
Infinity Pharmaceuticals, Inc.

Completed

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Solid Tumors

United States
Roswell Park Cancer Institute

Withdrawn

Icotinib Hydrochloride in Treating Patients With Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Healthy Subjects
Mylan Pharmaceuticals Inc

Completed

Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mg

Healthy

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
Daiichi Sankyo, Inc.

Completed

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
AstraZeneca

Completed

AZD9056 Relative Bioavailability Study

Healthy

United Kingdom
Mylan Pharmaceuticals Inc

Completed

Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Healthy

United States
PT. Pyridam Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of Metformin Hydrochloride 500 mg Film-Coated Tablets in Indonesia Healthy Subject

Drug Use

Indonesia
Teva Pharmaceuticals USA

Completed

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

Healthy

United States
Yabao Pharmaceutical Group

Completed

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Hyperglycaemia (Diabetic)

China
LG Chem

Unknown

Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions

Type2 Diabetes
Teva Pharmaceuticals USA

Completed

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting

Healthy

United States
Yabao Pharmaceutical Group

Completed

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

Healthy Volunteers | Hyperglycaemia (Diabetic)

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma

United States
Al-Rasheed University College

Completed

Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

Polycystic Ovary Syndrome

Iraq
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet

Metformin XR BE Study in Healthy Volunteers With Single and Multiple Dose

Indonesia
Cairo University

Recruiting

The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

Muscle-Invasive Bladder Carcinoma

Egypt
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer

Canada
Peking University First Hospital

Recruiting

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

Semaglutide | PCOS (Polycystic Ovary Syndrome)

China
SCRI Development Innovations, LLC
Infinity Pharmaceuticals, Inc.

Completed

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | T-cell Lymphoma

United States
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fed Conditions

Healthy

Canada
Actavis Inc.

Completed

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

Healthy

United States
Cairo University

Unknown

Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions

Oral Cancer

Egypt
MedSIR

Active, not recruiting

Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients (Phenomenal)

Breast Cancer Metastatic

Spain
Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
University of Sao Paulo General Hospital

Unknown

Laser and Therapeutic Ultrasound in the Management of the Chronic Non-specific Low Back Pain

Chronic Low Back Pain

Brazil
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions

Healthy

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

Healthy

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Relapsed T-Cell Lymphoma | Refractory T-Cell Lymphoma

United States
SecuraBio

Withdrawn

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

Search clinical trials for: retaspimycin hydrochloride (IPI-504)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations